Unknown PHASE3 INTERVENTIONAL 2-arm NCT00696748

The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men (NePlaM3)

A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men

Sponsor: Russian Academy of Medical Sciences

Conditions Hypogonadism Metabolic Syndrome

Interventions Nebido (testosterone undecanoate) Placebo

Updated 5 times since 2017 Last updated: Jun 11, 2008 Started: Oct 31, 2005 Primary completion: Jan 31, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypogonadism and Metabolic Syndrome, this trial is ongoing. The trial is conducted by Russian Academy of Medical Sciences and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Russian Academy of Medical Sciences

Data source: Russian Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia